Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
Open Access
- 14 July 2023
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (14) , 3531-3539
Abstract
Using tissue whole exome sequencing (WES) and circulating tumor cell–free DNA (ctDNA), this Australasian Leukaemia & Lymphoma Group translational study sought to characterize primary and acquired molecular determinants of response and resistance of marginal zone lymphoma (MZL) to zanubrutinib for patients treated in the MAGNOLIA clinical trial. WES was performed on baseline tumor samples obtained from 18 patients. For 7 patients, ctDNA sequence was interrogated using a bespoke hybrid-capture next-generation sequencing assay for 48 targeted genes. Somatic mutations were correlated with objective response data and survival analysis using Fisher exact test and Kaplan-Meier (log-rank) method, respectively. Baseline WES identified mutations in 33 of 48 (69%) prioritized genes. NF-κB, NOTCH, or B-cell receptor (BCR) pathway genes were implicated in samples from 16 of 18 patients (89%). KMT2D mutations (n = 11) were most common, followed by FAT1 (n = 9), NOTCH1, NOTCH2, TNFAIP3 (n = 5), and MYD88 (n = 4) mutations. MYD88 or TNFAIP3 mutations correlated with improved progression-free survival (PFS). KMT2D mutations trended to worse PFS. Acquired resistance mutations PLCG2 (R665W/R742P) and BTK (C481Y/C481F) were detected in 2 patients whose disease progressed. A BTK E41K noncatalytic activating mutation was identified before treatment in 1 patient who was zanubrutinib-refractory. MYD88, TNFAIP3, and KMT2D mutations correlate with PFS in patients with relapsed/refractory MZL treated with zanubrutinib. Detection of acquired BTK and PLCG2 mutations in ctDNA while on therapy is feasible and may herald clinical disease progression. This trial was registered at https://anzctr.org.au/ as #ACTRN12619000024145.Keywords
This publication has 40 references indexed in Scilit:
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor IbrutinibNew England Journal of Medicine, 2014
- Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphomaNature Medicine, 2013
- Targeting pathological B cell receptor signalling in lymphoid malignanciesNature Reviews Drug Discovery, 2013
- Function and cancer genomics of FAT family genesInternational Journal of Oncology, 2012
- A Hypermorphic Missense Mutation in PLCG2 , Encoding Phospholipase Cγ2, Causes a Dominantly Inherited Autoinflammatory Disease with ImmunodeficiencyThe American Journal of Human Genetics, 2012
- The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone developmentJournal of Experimental Medicine, 2012
- Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalitiesLaboratory Investigation, 2012
- Targeting NF-κB in Waldenstrom macroglobulinemiaBlood, 2008
- Structure, function and regulation of the Toll/IL‐1 receptor adaptor proteinsImmunology & Cell Biology, 2007
- Activation of bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domainImmunity, 1995